Hypertension in Africa Research Team (HART), North-West University (Potchefstroom Campus), Potchefstroom, South Africa.
Hypertension in Africa Research Team (HART), North-West University (Potchefstroom Campus), Potchefstroom, South Africa.
Heart Lung Circ. 2014 Feb;23(2):119-26. doi: 10.1016/j.hlc.2013.07.019. Epub 2013 Aug 24.
The use of antiretroviral treatment is known to be accompanied by several negative health outcomes and may negatively affect a country such as South Africa, which is the most burdened by the human immunodeficiency virus (HIV) in the world. We aimed to determine whether receiving antiretroviral treatment changes the cardiometabolic profile of HIV-infected South Africans.
In this sub-study, embedded in the Prospective Urban and Rural Epidemiology (PURE) study, we compared the cardiometabolic profile in a cohort of 66 treated and 71 never treated HIV-infected participants from the North-West province, South Africa. By using standard techniques, these participants' cardiometabolic, biochemical and lifestyle variables were assessed in 2005 and 2010, respectively.
The treated group showed a higher percentage change in pulse pressure (13.3%; p = 0.004), systolic blood pressure (4.5%; p = 0.029) and CD4 cell count (9.2%; p = 0.009) levels over five years. During follow-up (2010), lipid variables were worse in the treated group. Further, antiretroviral treatment was associated with the percentage change in pulse pressure (R(2) = 0.24; β = 0.19; p = 0.020).
We concluded that Africans receiving antiretroviral treatment had a greater increase in pulse pressure and systolic blood pressure, as well as an unfavourable lipid profile when compared to never treated participants. Whether, in the long term, antiretroviral treatment will lead to increased arterial stiffness and/or accelerated atherosclerosis among this HIV-infected African population remains to be seen.
抗逆转录病毒治疗的应用已知伴随着一些负面的健康结果，并可能对南非等国家产生负面影响，南非是世界上受人类免疫缺陷病毒（HIV）负担最重的国家。我们旨在确定接受抗逆转录病毒治疗是否会改变感染 HIV 的南非人的心脏代谢特征。
在这项子研究中，我们将纳入前瞻性城乡流行病学（PURE）研究，比较了来自南非西北省的 66 名接受治疗和 71 名从未接受治疗的 HIV 感染参与者的心脏代谢特征。通过使用标准技术，分别于 2005 年和 2010 年评估了这些参与者的心脏代谢、生化和生活方式变量。
治疗组在五年内的脉搏压（13.3%；p = 0.004）、收缩压（4.5%；p = 0.029）和 CD4 细胞计数（9.2%；p = 0.009）的百分比变化更高。在随访期间（2010 年），治疗组的血脂变量更差。此外，抗逆转录病毒治疗与脉搏压的百分比变化相关（R²=0.24；β=0.19；p=0.020）。
我们得出结论，与从未接受治疗的参与者相比，接受抗逆转录病毒治疗的非洲人脉搏压和收缩压增加幅度更大，血脂谱更差。长期来看，抗逆转录病毒治疗是否会导致该 HIV 感染非洲人群的动脉僵硬和/或动脉粥样硬化加速，还有待观察。
